Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06726785 · ClinicalTrials.gov registry record
Observe Change in Nasal Swab DRD2 Gene Expression in Restless Legs Syndrome (RLS) Patients on Prolonged Dopamine Agonist Treatment
A clinical trial of Restless Leg Syndrome (RLS), sponsored by HBC Immunology.
- Recruiting
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT06726785 is a study of Restless Leg Syndrome (RLS) that is actively recruiting participants, run by HBC Immunology. The registered enrollment target is 50 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06726785, a study of Restless Leg Syndrome (RLS), is actively recruiting participants, sponsored by HBC Immunology.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The study aims to observe changes in dopaminergic genes expression in peripheral tissue upon prolonged dopamine agonist treatment on patients with Restless Legs Syndrome (RLS). Similar studies in Parkinson's disease have shown changes in alpha-synuclein expression, which might offer insights into the dopaminergic gene regulation seen in RLS. The dopamine agonist drugs to be included in this study are: Pramipexole (Mirapex), Ropinirole (Requip), Rotigotine (Neupro), Apomorphine (Apokyn), Bromocriptine (Parlodel). Specifically, the study will collect nasal swabs of participants partitioned into two groups, those who have not used a dopamine agonist or been on a dopamine agonist for less than 1 month compared to those who have been on the medication for 6 or more months. This research could provide insight into changes in dopaminergic gene expression associated with Augmentation Syndrome (AS) which occurs after long term dopamine agonist treatment in RLS patients.
Conditions Studied
Study Locations (1)
California
- Alethios Inc - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-07-01 |
| Est. Completion | 2026-02-27 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06726785
The ClinicalTrials.gov registry entry for NCT06726785 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is HBC Immunology, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Restless Leg Syndrome (RLS) appearing as the primary indexed condition, and to 0 interventions.
NCT06726785 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06726785 about?
NCT06726785 is a clinical study titled "Observe Change in Nasal Swab DRD2 Gene Expression in Restless Legs Syndrome (RLS) Patients on Prolonged Dopamine Agonist Treatment". The study aims to observe changes in dopaminergic genes expression in peripheral tissue upon prolonged dopamine agonist treatment on patients with Restless Legs Syndrome (RLS). Similar studies in Parkinson's disease have shown changes in alpha-synuclein expression, which might offer insights into th...
What is the current status of trial NCT06726785?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2025-07-01. Estimated completion is 2026-02-27.
What conditions does trial NCT06726785 study?
This clinical trial studies the following conditions: Restless Leg Syndrome (RLS).
Who is sponsoring clinical trial NCT06726785?
This trial is sponsored by HBC Immunology, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06726785 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Restless Leg Syndrome (RLS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.